Iambic Therapeutics (formerly known as Entos) is a company that develops medicines using artificial intelligence technologies. It applies algorithms, high-throughput experimentation, and chemical synthesis to create compounds targeting proteins such as HER2, CDK2/4, and KIF18A for oncology and neurological disorders. The company serves the pharmaceutical and biotechnology industries.